Arctoris Ltd, an Oxford-based research company operating a fully automated drug discovery platform, has appointed three distinguished experts as members of its Advisory Board: Beth J Hoffman PhD, Professor Khusru Asadullah MD, and Stanley Lapidus. “We are delighted to see Dr Hoffman, Prof Asadullah and Mr Lapidus join our company’s Advisory Board at this exciting moment in Arctoris’ growth”, said Martin-Immanuel Bittner MD DPhil, CEO and Co-Founder of Arctoris. “Each of them brings deep industry knowledge and expertise that will be instrumental in executing our plans to become the global leader for robotics-powered drug discovery.”

Beth J Hoffman PhD is a seasoned pharmaceutical and biotech executive. Beth is the CEO of San Diego-based Origami Therapeutics. During her distinguished career she has also served as Vice-President of Discovery Biology at Vertex Pharmaceuticals and held leadership positions at Amgen, Eli Lilly, and the NIH. Beth brings invaluable experience in drug discovery and development, both from the R&D and business perspective.

Professor Khusru Asadullah MD, is a renowned academic and an authority in translational medicine with more than 15 years of industry experience. Khusru was the Vice-President & Head of Target Discovery at leading German pharma company Bayer. In this role, he led the industry-changing Bayer reproducibility study, which challenged the status quo in drug target identification. Khusru will advise Arctoris in translational and precision medicine, data standards, and best practices in drug discovery.

The third appointee is Stanley Lapidus, founder and former CEO of the CYTYC Corporation, founder and former chairman and CEO of Exact Sciences, and Executive in Residence at the University of Colorado. Stanley is a serial entrepreneur who brought two companies from idea to NASDAQ, and has unparalleled insights in the life sciences, biotech, and medtech arena. Stanley will support the management and the Board of Arctoris in developing and executing its global growth strategy.

New member of the Advisory Board, Beth J Hoffman, said: “On behalf of my two colleagues, I am honoured to join the Arctoris Advisory Board. I have spent several decades in drug discovery, and I believe it is time for a radically different approach that will allow us to generate better data faster and to accelerate the translation of new hypotheses into new drugs. Arctoris developed a unique technology platform, and assembled a world-class team to transform data generation in this space. I am proud to support Arctoris on its mission, and look forward to working with the company’s management and Board.”

ABOUT ARCTORIS LTD
Arctoris Ltd is an Oxford-based research company that is revolutionising drug discovery for biotechnology companies, pharmaceutical corporations and academia. Arctoris has established the world’s first fully automated drug discovery platform, offering pre-optimized and fully validated processes for its partners and customers globally. Accessible remotely, the platform provides on-demand access to a wide range of biochemical, cell biology and molecular biology assays conducted by robotics, enabling rapid, informed decision-making in basic biology, target validation, toxicology and phenotypic screening. These assay capabilities are accessed using a powerful online portal that streamlines experiment planning, ordering, tracking and data analysis. Thanks to the Arctoris platform, partners and clients can rapidly, accurately and cost-effectively perform their research and advance their drug discovery programs.

For more information, please visit www.arctoris.com or follow us on LinkedIn and Twitter.